Salicylalazine: A Novel Therapeutic Agent Targeting TLR4/NLRP3/GSDMD-Mediated Pyroptosis in Rheumatoid Arthritis
International immunopharmacology | Vol. 145 | 2024
DOI: https://doi.org/10.1016/j.intimp.2024.113778